Nov 9 (Reuters) - Aralez Pharmaceuticals Inc ARZ.TO
* Aralez announces third quarter 2017 financial results and achieves profitability on an adjusted EBITDA basis for the first time in the third quarter
* Aralez Pharmaceuticals Inc - provides updated 2017 full-year guidance and preliminary 2018 full-year outlook
* Aralez Pharmaceuticals Inc - plans to implement further financial improvements designed to streamline U.S. business
* Aralez Pharmaceuticals Inc - net loss in Q3 of 2017 was $24.4 million, or $0.37 per diluted share
* Qtrly total revenues, net $24.3 million versus $13.6 mln
* Aralez Pharmaceuticals Inc - updated 2017 net revenues to be in a range of $95 million to $105 million
* Aralez Pharmaceuticals Inc - sees 2018 net revenues $140 million to $160 million